News about Market

Novo Nordisk Makes Unsolicited USD 6.5 Billion Bid to Acquire Metsera

Novo Nordisk, a leading global healthcare company founded in 1923 and headquartered in Denmark, has announced that it has submitted an unsolicited proposal to acquire Metsera, Inc.

Market | 01/11/2025 | By Darshana |  246

Breckenridge Launches Everolimus Tablets, 1mg, generic version of Zortress

Breckenridge Pharmaceutical has announced the launch of Everolimus Tablets, 1 mg, the generic equivalent of Zortress. An mTOR inhibitor immunosuppressant, Everolimus is indicated for the prevention of organ rejection in adult kidney and liver transplant patients and will be available through retail, mail-order pharmacies, and clinics.

Market | 31/10/2025 | By Dineshwori |  336

LillyDirect and Walmart Pharmacy Launch Retail Pick-Up for Zepbound at DTC Pricing

Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials.

Market | 30/10/2025 | By Dineshwori |  452

GSK and Empirico Sign Licensing Deal for Respiratory Oligonucleotide

Oligonucleotide therapies, including siRNA, offer the potential to modulate gene expression and target diseases beyond the reach of traditional drugs. EMP-012 adds to GSK’s growing oligonucleotide pipeline across respiratory, immunology and inflammation, and infectious disease portfolios.

Market | 29/10/2025 | By Dineshwori |  270

Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb

Evotec has reported advancement in its preclinical neuroscience collaboration with Bristol Myers Squibb, securing a payment of USD 25 Million to support the continued development of jointly pursued therapeutic programmes.

Market | 28/10/2025 | By Dineshwori |  234

Novartis agrees to acquire Avidity Biosciences

Novartis has announced a definitive agreement to acquire Avidity Biosciences, a move aimed at expanding its neuroscience portfolio with advanced programs targeting rare genetic neuromuscular disorders.

Market | 27/10/2025 | By Dineshwori |  267

Alkermes Enters Sleep Medicine Arena with USD 2.1 Billion Acquisition of Avadel

Alkermes plc has announced it will acquire Avadel Pharmaceuticals in a deal valued at up to USD 2.1 billion, marking the company’s strategic entry into the sleep medicine market.

Market | 24/10/2025 | By Darshana |  211

Lupin Launches Generic Version of Ravicti in the US

Global pharma major Lupin has launched an authorised generic version of Ravicti (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States.

Market | 24/10/2025 | By Dineshwori |  226

Biocon Biologics and Civica Launch Private-Label Insulin Glargine in the US

The multi-year transformational agreement between Biocon Biologics and Civica creates an exclusive distributorship arrangement where Biocon Biologics will manufacture and supply Insulin Glargine medicine to Civica, and Civica will commercialise under Biocon Biologics’ existing marketing approval.

Market | 21/10/2025 | By Dineshwori |  244

Pelage Pharma Raises USD 120 Million to Advance Regenerative Hair Loss Therapy

Pelage Pharmaceuticals, a Los Angeles-based clinical-stage regenerative medicine company, has raised USD 120 million in a Series B funding round to accelerate the development of its innovative treatment for hair loss. The financing was co-led by ARCH Venture Partners and GV (formerly Google Ventures), with participation from existing investors.

Market | 17/10/2025 | By Darshana |  193